Narrow-moat Bio-Rad faced some headwinds in the first quarter from lower COVID-19 sales and supply chain challenges, though growth declines were not as bad as feared and margin held up well. Our $524 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback